Sanofi Pasteur Selects Freeslate to Improve Formulation Development
Sanofi Pasteur has purchased Freeslate?s Biologics Formulation System for accelerating research in vaccine and protein formulation development.
Freeslate, a provider of high-throughput research solutions, reports that Sanofi Pasteur, the vaccines division of Sanofi, has purchased Freeslate’s Biologics Formulation System, which is usual in vaccine and protein formulation development. The system automates sample preparation, sample stressing, and formulation analysis, to allow for the development of stable, robust formulations more quickly with reduced API consumption.
Based on the Freeslate Core Module 3 automation platform, the Biologics Formulation System combines liquid dispense and controlled heating/cooling/mixing with new automated measurements of pH, viscosity, and particle counting. Integrated by Freeslate’s Lab Execution and Analysis software suite, the system allows for the control and data integration of a range of third-party analytics, including Dynamic Light Scatter, UV/VIS plate readers, and high pressure liquid chromatography.
Source: Freeslate
